Epizyme, Inc.
(NASDAQ : EPZM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 8.73%147.660.0%$994.17m
AMGNAmgen, Inc. 0.87%255.261.5%$856.48m
GILDGilead Sciences, Inc. 0.51%64.801.0%$543.24m
VRTXVertex Pharmaceuticals, Inc. 1.51%273.731.9%$497.98m
REGNRegeneron Pharmaceuticals, Inc. 1.37%692.802.6%$444.80m
ILMNIllumina, Inc. 5.95%258.063.3%$337.13m
NVAXNovavax, Inc. 17.46%55.2975.7%$314.14m
BIIBBiogen, Inc. 0.97%206.201.8%$237.64m
BNTXBioNTech SE 5.57%166.960.0%$224.59m
SNSSSunesis Pharmaceuticals, Inc. 2.38%2.150.7%$150.29m
EXASEXACT Sciences Corp. 7.96%53.8317.7%$134.25m
TECHBio-Techne Corp. 5.81%386.564.5%$107.96m
TXG10X Genomics, Inc. 11.91%52.990.0%$106.79m
BMRNBioMarin Pharmaceutical, Inc. 2.68%80.974.2%$95.42m
CRSPCRISPR Therapeutics AG 5.63%58.340.6%$85.42m

Company Profile

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.